Ozempic and Gallbladder Disease: When to Call the Doctor

What the Ozempic label says about the gallbladder

Ozempic is semaglutide, a GLP-1 receptor agonist given as a once-weekly subcutaneous injection, with maintenance doses of 0.5 mg, 1 mg or 2 mg [1]. It is approved for type 2 diabetes: to improve glycemic control, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It has no weight-loss indication [1].

Its Warnings and Precautions include a section headed Acute Gallbladder Disease, which states that if cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated [1]. The label also lists cholecystitis and cholecystectomy among postmarketing reports, which are voluntary and cannot be used to estimate how often they happen [1].

The figures below come from a large cardiovascular outcomes trial of semaglutide 2.4 mg and from pooled analyses of GLP-1 receptor agonist trials [2][3][4].

How often does gallbladder disease occur with semaglutide?

The clearest single set of numbers comes from SELECT, which enrolled 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or higher but no diabetes, and followed them for a mean of 39.8 months. Gallbladder-related disorders were reported in 2.8% of those on semaglutide 2.4 mg versus 2.3% on placebo (p=0.04), mainly gallstones, at 1.4% versus 1.1%. Cholecystitis occurred in 0.6% of both groups [2].

Across the drug class, a meta-analysis of 21 randomized trials covering 99,599 patients and eight different GLP-1 receptor agonists found gallbladder disorders 26% more often with the drugs than with control, alongside a 63% increase in gastrointestinal disorders [3].

Focused on semaglutide, a meta-analysis of nine randomized trials in people with overweight or obesity and no diabetes, with 11,641 on semaglutide and 10,479 on placebo, reported gallbladder disorders at an odds ratio of 1.26 (p=0.010) and cholelithiasis at an odds ratio of 2.06 (p=0.04) [4].

Nausea, stomach pain, or something that needs a call?

Nausea is the most common complaint on Ozempic. In the label's pooled placebo-controlled trials it occurred in 15.8% on 0.5 mg and 20.3% on 1 mg versus 6.1% on placebo; abdominal pain in 7.3% and 5.7% versus 4.6%; vomiting in 5% and 9.2% versus 2.3%; diarrhea in 8.5% and 8.8% versus 1.9%; and constipation in 5% and 3.1% versus 1.5% [1]. Most reports of nausea, vomiting and diarrhea came during dose escalation, and severe gastrointestinal reactions occurred in 0.4% on 0.5 mg and 0.8% on 1 mg versus 0% on placebo [1].

When to call the doctor

Call promptly about abdominal pain that is new, keeps coming back or does not go away, rather than waiting for the next scheduled visit. The Ozempic label says gallbladder studies are indicated if gallstones or gallbladder inflammation are suspected [1].

Pain that is persistent or severe, sometimes radiating to the back and with or without nausea or vomiting, is the label's description of possible pancreatitis. The label says to discontinue Ozempic and start appropriate management if pancreatitis is suspected [1].

Vomiting and diarrhea are common on this drug. The label says most reported cases of acute kidney injury occurred in people whose nausea, vomiting or diarrhea led to dehydration, and that renal function should be monitored in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1].